Biovest closes $8.5 million financing
The proceeds from the loan will be used in part to finance the analysis of unblinded data on BiovaxID, an active immunotherapeutic in a pivotal Phase III study
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.